Mergers & AcquisitionsMedium•14 October 2026•
1 min read
Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences
Key Facts
1Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences, which is now a wholly-owned subsidiary.
2The transaction adds two clinical-stage therapeutic programs, GV104 and GV023, to the company's portfolio.
Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences, which is now a wholly-owned subsidiary. ACCESS Newswire reported that the transaction adds two clinical-stage therapeutic programs, GV104 and GV023, to the company's portfolio.
The acquisition aims to create a three-program portfolio spanning therapeutics and diagnostics, specifically targeting serious liver and inflammatory diseases. This strategic move expands the company's clinical-stage candidates within the biotechnology sector.